Ani Pharmaceuticals (ANIP) Total Current Liabilities (2010 - 2026)

Ani Pharmaceuticals has disclosed Total Current Liabilities across 17 years of filings, most recently posting $283.7 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 19.77% year-over-year to $283.7 million; the TTM figure through Jun 2026 stood at $283.7 million (up 19.77% YoY), while the FY2025 annual figure was $278.1 million, up 43.02% from the prior year.
• Total Current Liabilities came in at $283.7 million for Q2 2026 at Ani Pharmaceuticals, up from $239.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $283.7 million in Q2 2026 to a low of $79.5 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $169.8 million, with a median of $142.7 million recorded in 2023.
• Year-over-year, Total Current Liabilities fell 3.91% in 2022 and soared 69.19% in 2025.
• Over 5 years, Total Current Liabilities stood at $99.4 million in 2022, then soared by 46.3% to $145.5 million in 2023, then surged by 33.67% to $194.5 million in 2024, then soared by 43.02% to $278.1 million in 2025, then climbed by 1.99% to $283.7 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $283.7 million in Q2 2026, $239.5 million in Q1 2026, and $278.1 million in Q4 2025.